* Maravai LifeSciences Holdings Inc MRVI.OQ MRVI.O is
expected
to show a fall in quarterly revenue when it reports results on
February 22.
* The San Diego California-based company is expected to
report a
10.3% decrease in revenue to $204.931 million from $228.44
million a year ago, according to the mean estimate from 11
analysts, based on Refinitiv data. The company's guidance on
November 2 2022, for the period ended December 31, was for
revenue of $207.000 million.
* Refinitiv's mean analyst estimate for Maravai
LifeSciences
Holdings Inc is for earnings of 34 cents per share. The
company's EPS guidance on November 2 2022, for the period ended
December 31, was about USD0.33
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Maravai
LifeSciences Holdings Inc is $25, above its last closing price
of $14.70.
The company's guidance on November 2 2022 for the period ended
December 31 was for Earnings before Interest, Taxes,
Depreciation and Amortization of of USD147 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 0.33 0.33 0.37 Beat 12.2
Jun. 30 2022 0.45 0.45 0.54 Beat 18.8
Mar. 31 2022 0.44 0.44 0.54 Beat 23
Dec. 31 2021 0.38 0.38 0.45 Beat 17.1
Sep. 0.36 0.35 0.44 Beat 24.9
30 2021
Jun. 30 2021 0.32 0.32 0.44 Beat 39
Mar. 31 2021 0.21 0.21 0.26 Beat 26.6
Dec. 31 2020 0.11 0.11 0.13 Beat 20.3
This summary was machine generated February 20 at 23:36 GMT.
All figures in US dollars unless otherwise stated